The researchers identified molecular subtypes of head and neck cancer that could be susceptible to CDK inhibitor, anti-EGFR antibody, or immunotherapy treatments.
The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.
The firm's platform, dubbed HNKlear, uses methylation-specific PCR to detect microRNA biomarkers in a patient's blood sample following frontline cancer treatment.
The company will work with university researchers to evaluate its predictive immune modeling technology in personalizing the use of immune checkpoint inhibitors.
The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
